Market News & Trends
Idenix Provides Update on Clinical Development Programs
Idenix Pharmaceuticals, Inc. recently announced data from a Phase I clinical trial of IDX719, an NS5A inhibitor for the treatment of hepatitis C virus (HCV)…
NuSil Technology Announces Major Expansion
NuSil Technology LLC, the global leader in silicone materials for the healthcare, aerospace, pharmaceutical, aircraft, and drug delivery industries, recently announced plans for a major…
Spinnovation Biologics Predicts Biomanufacturing Success
With expertise and know-how in high-end analysis for biologics, Spinnovation Biologics recently announced the launch of a breakthrough solution -Spedia-Predict- for Bioprocess performance troubleshooting and…
SeraCare Expands AccuCell Line With Human Cord Blood Mononuclear Cells
SeraCare Life Sciences recently announced it has expanded its line of AccuCell mononuclear cells with the launch of off-the-shelf Human Cord Blood Mononuclear Cells (CBMNCs).…
US CMO Market Revives as Pharma Companies Increasingly Outsource
The upturn in the fortunes of pharmaceutical companies after the recession is mirrored by the US CMO market, which is expected to grow at a…
4/17/2012
Ei Increases Capabilities Through New Partnership Ei, A Pharmaceutical SolutionWorks, recently announced a new partnership with KeraNetics. Ei has begun a $13.2-million expansion within their…
Ei Increases Capabilities Through New Partnership
Ei, A Pharmaceutical SolutionWorks, recently announced a new partnership with KeraNetics. Ei has begun a $13.2-million expansion within their recently completed 147,000-sq-ft facility in Kannapolis,…
Horizon Partners With EMQN to Minimize Variability in Cancer Diagnostic Testing
Horizon Diagnostics (HDx), a division of Horizon Discovery Limited, a leading provider of research tools to support the development and prescription of personalized medicines, recently…
Nascent & Catalent Sign Cancer Antibody Development Deal
Nascent Biologics, Inc. and Catalent Pharma Solutions recently announced the signing of a product development agreement. Under the terms of the agreement, Catalent will engineer…
QRxPharma Successfully Completes Phase I Studies
QRxPharma recently announced successful completion of two Phase I studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilizing a 3:2 ratio of morphine…
4/10/2012
Catalent & BASF Join Forces to Solve Bioavailabilty Challenges Catalent Pharma Solutions and BASF recently announced they have entered into a broad collaboration and Open…
Amgen Signs $50-Million Deal to Develop Five Biotech Drugs
Amgen and AstraZeneca recentlyannounced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio: AMG 139, AMG 157, AMG 181,…
Astex Announces Interim Phase I/II AML Data
Astex Pharmaceuticals, Inc. recently announced that interim Phase I/II clinical data from subcutaneous SGI-110, a novel hypomethylating agent, demonstrated differentiated PK profile, good tolerability, and…
Catalent & BASF Join Forces to Solve Bioavailabilty Challenges
Catalent Pharma Solutions and BASF recently announced they have entered into a broad collaboration and Open Alliance to provide solutions to overcome bioavailability challenges of…
GlaxoSmithKline to Increase Its Ownership in Theravance
GlaxoSmithKline plc (GSK) and Theravance, Inc. recently announced they have entered into a stock purchase agreement, under which Theravance will issue, and GSK will acquire,…
OvaScience Raises $37 Million in Series B Financing
OvaScience recently announced it has completed a $37-million Series B financing. The financing was led by General Catalyst. Existing investors, Bessemer Venture Partners and Longwood…
Spectrum Pharmaceuticals to Acquire Allos Therapeutics
Spectrum Pharmaceuticals and Allos Therapeutics, Inc. recently announced they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of…
4/3/2012
Aptar Pharma's Device Delivers INSYS Therapeutics' Drug Aptar Pharma recently announced INSYS Therapeutics' SUBSYS, which uses an Aptar Pharma Sublingual Unit-Dose Spray (UDS) device, has…
Allena Pharmaceuticals Licenses Worldwide Rights to Hyperoxaluria Portfolio
Allena Pharmaceuticals, Inc. and Althea Technologies recently announced a licensing agreement under which Allena has obtained the exclusive worldwide rights to Althea's broad hyperoxaluria portfolio,…
Aptar Pharma's Device Delivers INSYS Therapeutics' Drug
Aptar Pharma recently announced INSYS Therapeutics' SUBSYS, which uses an Aptar Pharma Sublingual Unit-Dose Spray (UDS) device, has been launched in the US for breakthrough…
